UK accepts AI commission regs as MHRA opens Airlock Phase 3

The UK government has that it would accept all recommendations from the National Commission into the Regulation of AI in Healthcare.
Its response sets out plans for a more proportionate, lifecycle-based approach to AI-enabled medical devices, with greater emphasis on monitoring their performance throughout their working life.
Today’s response commits the UK to developing a world-leading agile approach to AI device regulation that supports innovation while maintaining patient safety and public trust.
The reforms aim to ensure patients can benefit from safe, effective and trusted AI more quickly, while maintaining robust safeguards as technologies evolve.
Health innovation minister James Frith said: “We want all patients to benefit from the life-saving potential of AI, with the confidence that it is safe, effective and properly overseen.
“We also want to see the NHS harness the best new technologies to give patients faster, better care and give staff more time to focus on patients. But innovation must never come at the expense of patient safety.
“This will be a continually-evolving process as the technology itself develops, but we are acting now by accepting in full all 44 recommendations of the Independent Commission, which will provide a foundation to embrace the opportunities AI brings while putting strong safeguards, transparency and public confidence at the heart of its use.”
Alongside the announcement, the MHRA has opened applications for Phase 3 of AI Airlock, its regulatory sandbox for AI-enabled medical devices.
The programme will focus on post-market surveillance, meaning monitoring devices after deployment, and lifecycle regulation.
Developers, regulators and healthcare partners will examine how AI-enabled medical devices can be monitored and managed after deployment.
The first wave of participants is due to be selected in November 2026.
The MHRA has also committed to issuing draft guidance by December 2026 on managing changes to AI-enabled medical devices as the technologies adapt and improve over time.
It plans to consult next year on how AI-enabled devices should be qualified and classified, addressing the Commission’s first recommendation.
The response also includes plans to explore staged authorisation pathways that could allow some AI technologies to be used in the NHS under close supervision while further evidence from real-world use is collected.
A full implementation roadmap covering timelines and responsibilities for all 44 recommendations is due by spring 2027, followed by regular progress updates.
Lawrence Tallon, chief executive of the MHRA, said: “The independent National AI Commission, led by NHS doctors, has given us a clear and ambitious blueprint for how we make the UK the best place to get AI products to patients safely, quickly and in a way that maintains public trust.
“I am pleased that today the Government is accepting its recommendations in full, whilst setting out a clear plan and oversight structure to deliver them.
“The MHRA’s AI Airlock is already opening its doors to more innovators who want to help us understand how these technologies can be implemented and monitored safely throughout their working life.
“This is about making sure patients can benefit from safe, trusted AI more quickly, while never losing sight of the safeguards that maintain public confidence.”










